Replies to post #209654 on Biotech Values

[Bickema]

RVNC - Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines

http://investors.revance.com/releasedetail.cfm?ReleaseID=1016225